'gamechanger' etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
'gamechanger' etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

22 Mart 2017 Çarşamba

Why virtual reality could be a mental health gamechanger

Few tech topics are hotter right now than virtual reality (VR). Though it’s been around for decades, VR has at last entered the world of consumer electronics via devices like the Oculus Rift and HTC Vive and, increasingly, headsets that can be used in conjunction with our mobile phones. But VR isn’t just a technological game-changer: it could transform the way we tackle mental health problems.


Not so long ago, talking about psychological problems was taboo. Now the scale of these disorders is no longer a secret. We know, for example, that one in four people will experience mental health issues at some point in their life. The ramifications from this ocean of distress aren’t merely personal; the socio-economic consequences are profound. Nearly half of all ill health in working age adults in the UK is psychological. Mental illness costs the UK economy £28 billion every year — and that’s excluding NHS costs.


But if the problem is so huge, what are we doing about it? When it comes to funding, psychological disorders are very much the poor relation, receiving just 5% of medical research funding and 13% of NHS health expenditure. Treatment options have increased since 2007 via the Improving Access to Psychological Therapies scheme, but we’re still a long way from being able to provide timely treatment to everyone who needs it.


And the form of that treatment is crucial. Counselling can be effective to a degree, but the most powerful changes happen when individuals are presented with the situations that cause them distress and directly learn how to think, feel, and behave more constructively. That means getting out of the consulting room and into the real world, with the therapist acting much more like a personal trainer or leadership coach. Unfortunately, this seldom occurs: even when therapists recognise the desirability of the approach, time is at a premium.


The picture, then, is not a happy one — a major public health problem and an inability to provide the best therapies to the majority of those affected. And yet we may be on the brink of a startling breakthrough, thanks to a technology that has been with us for half a century.


Virtual reality was first developed at MIT in the mid-1960s. The essential elements haven’t changed greatly over the years — a computer generates an image, a display system presents the sensory information, and a tracker feeds back the user’s position and orientation in order to update the image — but what’s new is the sophistication and affordability of the technology.


Despite the massive investment in VR on the part of companies such as Facebook (who bought Oculus in 2014 for $ 2bn), the technology has so far struggled to gain a foothold beyond the gaming market. So what can it bring to the world of mental health?


The answer lies in VR’s extraordinary ability to create powerful simulations of the scenarios in which psychological difficulties occur. Suddenly there’s no need for a therapist to accompany a client on a trip to a crowded shopping centre, for example, or up a tall building. Situations that are more or less impossible to build into a course of therapy — flying, for example, or the shocking events that often lie behind PTSD — can be conjured at the click of a mouse. The in-situ coaching that’s so effective for so many disorders can now be delivered in the consulting room, with the simulations graded in difficulty and repeated as often as necessary.


VR offers another great advantage. Understandably, the thought of facing a difficult situation — even as part of a course of therapy — can be off-putting for many people. But because VR is not real that reticence tends to disappear. We’ll do things in VR that we’d be reluctant to try in normal life. Yet although the computer-generated environment is artificial, our mind and body behave as if it were natural. And that means that the lessons we learn in VR transfer to the real world.


So where do things stand with VR and psychological therapy? We’ve just completed the first review of every study that has used VR to assess, understand, and treat mental health conditions. The earliest was undertaken almost 25 years ago, at a time when the cost and complexity of the equipment and programming meant that research was confined to a very small number of specialist centres. Since then 285 studies have been published. Most of those have focused on using VR to treat anxiety disorders and particularly phobias, social anxiety, and PTSD. The results have been encouraging — VR is a proven means of delivering rapid, lasting improvements.


When it comes to other disorders, however, the story so far is one of potential. The work we’ve done on tackling the persecutory delusions often seen in psychosis suggests that VR can be of huge value, but more research is needed. Just two small pilot studies have used VR to tackle depression, which of course is one of the most prevalent psychological problems. We know that the technology is effective at triggering the cravings associated with alcohol abuse and smoking, but no one has properly tested a VR-based treatment. Similarly, because VR is able to alter the way we perceive our bodies it could be hugely helpful in treating eating disorders (one study, for instance, helped anorexia patients to experience a healthy BMI body and for a short time afterwards the individuals were less likely to overestimate their weight). But to date systematic therapeutic studies of VR for eating disorders haven’t been done.


With the exception of anxiety disorders, then, it’s early days for VR and mental health. But what we’ve already seen is that the potential is huge, not only for therapy but also for assessment: rather than relying on what people can remember of their thoughts and feelings, VR will allow clinicians to run powerful situational tests. Moreover, we may not be far off the time when we can all use VR to improve our psychological well-being from the comfort and security of our own homes. Current VR treatments require a trained therapist to be present; future versions could be delivered by a virtual therapist, making the best psychological science available to far greater numbers of us than ever before.


Getting to that point, however, will require significant strategic leadership and investment. When it comes to hardware, VR could turn out to be more important in mental health than brain scanners. Yet, to our knowledge, our mental health research team in Oxford is the only one in the UK to have a full-time VR post.


Not only does the psychological component of virtual therapies need to be appropriate, the VR experience must be up to scratch. Much so-called VR is miles away from the revolutionary immersive technology it can be. When VR is done properly it’s a breath-taking adventure for users. Virtual therapies will need to be just as exciting as the very best computer games if they are to keep us coming back for more.


Moreover, we mustn’t forget that VR doesn’t merely allow us to simulate reality — it allows us to create situations that could never happen in real life. We did just this a couple of years back when we altered people’s perceived height in a VR environment and tracked the impact on their self-esteem. VR therapies must aim to exploit the incredible imaginative capacity of the technology.


And of course, rather more prosaically but no less important, VR treatments must be tested in rigorous clinical trials.


Much work is required then. But the benefits could be extraordinary. Many have said that VR is a technology in search of a purpose. In mental health, it may just have found one.


Daniel and Jason Freeman can be found on Twitters as @ProfDFreeman and @JasonFreeman100



Why virtual reality could be a mental health gamechanger

16 Kasım 2016 Çarşamba

Long-lasting pill that releases drugs for two weeks a "game-changer"

A pill that releases its medicine for two weeks after being swallowed is being hailed as a potential game-changer in drug treatment.


In future, similar forms of longterm oral drug delivery could put an end to regimens requiring numerous repeat doses, which may be missed or found too inconvenient.


The prototype capsule was tested with a malaria drug called ivermectin. Used in mass treatment campaigns, it could aid eventual elimination of the disease, say experts.


Long-acting pills could be especially helpful for elderly patients or those with mental conditions who often fail to follow prescription instructions.


Prof Robert Langer, a member of the Massachusetts Institute of Technology (MIT) team that developed the pill in the US, said: “Until now, oral drugs would almost never last for more than a day. This really opens the door to ultra-long-lasting oral systems, which could have an effect on all kinds of diseases, such as Alzheimer’s, or mental health disorders.”


The pill has a star-shaped structure with six arms that can be folded inwards and encased in a smooth capsule. Drug molecules are loaded into the arms. After the capsule is swallowed, stomach acid dissolves its outer layer, allowing the arms to unfold and release their payload.


Once expanded, the “star” is large enough to stay in the stomach and resist being pushed further down the digestive tract. However, it is not so large that there is a risk of blockage. Eventually, the arms break off and the pieces are expelled naturally.


Tests in pigs showed that the pill could keep releasing its medicine in the stomach for two weeks. Future versions of the capsule are expected to provide even longer-lasting drug delivery, spanning a month or more.


Co-author Dr Giovanni Traverso, from Harvard Medical School, said: “We want to make it as easy as possible for people to take their medications over a sustained period of time. When patients have to remember to take a drug every day or multiple times a day, we start to see less and less adherence to the regimen. Being able to swallow a capsule once a week or once a month could change the way we think about delivering medications.”


A new US company spun off the research, Lyndra, is now developing the technology with a view to focusing on neuropsychiatric disorders, HIV, diabetes and epilepsy.


Dr Andrew Billinger, chief scientific officer at Lyndra, said longterm delivery of ivermectin using the pill could assist malaria elimination campaigns based on treating whole populations. “Getting patients to take medicine day after day after day is really challenging,” he added.


Andrew Boaden, senior policy officer at the Alzheimer’s Society, said: “Seven in 10 people with dementia have at least one other health condition such as diabetes or heart disease, which often means they are taking a cocktail of different drugs throughout the day.


“Innovations that allow treatments to be taken less frequently have the potential to help people with dementia avoid missing their medication and falling sick.


“It’s important to note that we don’t yet know whether this method could be used for specific medications and dementia treatments – this would require further testing.”


The research is reported in the journal Science Translational Medicine.



Long-lasting pill that releases drugs for two weeks a "game-changer"

9 Ekim 2016 Pazar

Immunotherapy drug a "gamechanger" for head and neck cancer

An immunotherapy drug hailed as a potential “gamechanger” in the treatment of cancer could soon offer new hope to patients with currently untreatable forms of the disease.


Nivolumab was found to extend the lives of relapsed patients diagnosed with head and neck cancers who had run out of therapy options. After a year of treatment, 36% of trial patients treated with the drug were still alive compared with 17% of those given standard chemotherapy.


Patients with advanced head and neck cancers resistant to chemotherapy are notoriously difficult to treat and generally survive less than six months.


Trial participants treated with nivolumab typically survived for 7.5 months, and some for longer. Middle-range survival for patients on chemotherapy was 5.1 months.


The phase-three study, the last stage in the testing process before a new treatment is licensed, provided the first evidence of a drug improving survival in this group of patients.


Prof Kevin Harrington, from the Institute of Cancer Research, London, who led the British arm of the international trial, said: “Nivolumab could be a real gamechanger for patients with advanced head and neck cancer. This trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.


“Once it has relapsed or spread, head and neck cancer is extremely difficult to treat. So it’s great news that these results indicate we now have a new treatment that can significantly extend life, and I’m keen to see it enter the clinic as soon as possible.”


Before it can be offered on the NHS, the treatment will have to be approved by the European Medicines Agency and the National Institute for Health and Care Excellence (Nice), which vets new therapies in England and Wales for cost-effectiveness.


Of the 361 patients enrolled in the trial, 240 were given nivolumab while the remaining 121 received one of three different chemotherapies. UK patients were assigned the chemotherapy drug docetaxel, the only treatment currently approved for advanced head and neck cancer by Nice.


Patients whose tumours tested positive for the HPV virus, which is linked to cervical cancer and may be spread by oral sex, did especially well. They typically survived for 9.1 months, compared with 4.4 months when treated with chemotherapy.


The findings were simultaneously published in the New England Journal of Medicine and presented at the European Society for Medical Oncology (Esmo) conference in Copenhagen.


In 2012 around 11,000 new cases of head and neck cancer were diagnosed in the UK and 3,300 Britons died from the disease. The cancer can effect the lips, mouth, nasal cavity, back of the throat, and voice box.


More than half of patients relapse within three to five years.


Nivolumab is one of a new class of antibody drugs called “checkpoint inhibitors” that help the immune system fight cancer. It works by blocking signals from tumour cells that stop the immune system attacking.


The drug is already licensed for the treatment of advanced melanoma skin cancer and non-small-cell lung cancer in the UK.


However while Nice has backed its use on the NHS for melanoma it has so far refused to recommend making the drug freely available to lung cancer patients.


Prof Paul Workman, chief executive of the Institute of Cancer Research, said: “Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment. This phase-three clinical trial expands the repertoire of nivolumab even further, showing that it is the first treatment to have significant benefits in relapsed head and neck cancer.


“We hope regulators can work with the manufacturer to avoid delays in getting this drug to patients who have no effective treatment options left to them.”



Immunotherapy drug a "gamechanger" for head and neck cancer